Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScopeⓇ—Global Registry for Emerging Fungal Infections

Jon Salmanton-García; Philipp Koehler; Anupma Kindo; Iker Falces-Romero; Julio García-Rodríguez; Zdeněk Ráčil; Sharon C.A. Chen; Nikolai Klimko; Guillaume Desoubeaux; George R. Thompson; Miguel Ángel Benítez-Peñuela; José Yesid Rodríguez; Donald C. Sheppard; Martin Hoenigl; Yohann Le Govic; Hamid Badali; John W. Baddley; Jagdish Chander; Paul R. Ingram; Diana L. Pakstis; Sibylle C. Mellinghoff; Serkan Atıcı; Simone Cesaro; Arunaloke Chakrabarti; Damien Dupont; Gloria M. González; Lóránt Hatvani; Raoul Herbrecht; Galina Klyasova; Cornelia Lass-Flörl; Mihai Mareș; Kathleen Mullane; Donald C. Vinh; Hilmar Wisplinghoff; Michaela Lackner; Oliver A. Cornely; Danila Seidel; Barbara D. Alexander; María Almagro-Molto; Eduardo Álvarez-Duarte; Martha Avilés-Robles; Aleksandra Barać; Vanda Chrenková; Patricia Cornejo-Juárez; Nicole Desbois-Nogard; Mario Fernández-Ruiz; Luis Figueira; Jesús García-Martínez; Sandra Gräber; Barbara Graf; Georg Haerter; Shariq Haider; Pamela Hartman; Melina Heinemann; Aamer Ikram; Frédéric Janvier; Jeffrey D. Jenks; Carol Kauffman; Robert Krause; Me Linh Luong; Shruti Malik; Vincent Marconi; Rodrigo Martino; Sanjay R. Mehta; Lisa Meintker; Andrea Mocná; Michele I. Morris; Alessandro C. Pasqualotto; Atul Patel; Olaf Penack; Nicolas Pichon; Mathias W. Pletz; Carlos Seas; Uluhan Sili; Monica Slavin; Kenji Uno; Jose A. Vazquez; Thomas Weber; Barbora Weinbergerova; Deniz Yilmaz-Karapinar; Seda Yilmaz-Semerci; Jin Yu

doi:10.1016/j.jinf.2020.08.015

Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope^Ⓡ—Global Registry for Emerging Fungal Infections

Jon Salmanton-García, Philipp Koehler, Anupma Kindo, Iker Falces-Romero, Julio García-Rodríguez, Zdeněk Ráčil, Sharon C.A. Chen, Nikolai Klimko, Guillaume Desoubeaux, George R. Thompson, Miguel Ángel Benítez-Peñuela, José Yesid Rodríguez, Donald C. Sheppard, Martin Hoenigl, Yohann Le Govic, Hamid Badali, John W. Baddley, Jagdish Chander, Paul R. Ingram, Diana L. PakstisSibylle C. Mellinghoff, Serkan Atıcı, Simone Cesaro, Arunaloke Chakrabarti, Damien Dupont, Gloria M. González, Lóránt Hatvani, Raoul Herbrecht, Galina Klyasova, Cornelia Lass-Flörl, Mihai Mareș, Kathleen Mullane, Donald C. Vinh, Hilmar Wisplinghoff, Michaela Lackner, Oliver A. Cornely, Danila Seidel, Barbara D. Alexander, María Almagro-Molto, Eduardo Álvarez-Duarte, Martha Avilés-Robles, Aleksandra Barać, Vanda Chrenková, Patricia Cornejo-Juárez, Nicole Desbois-Nogard, Mario Fernández-Ruiz, Luis Figueira, Jesús García-Martínez, Sandra Gräber, Barbara Graf, Georg Haerter, Shariq Haider, Pamela Hartman, Melina Heinemann, Aamer Ikram, Frédéric Janvier, Jeffrey D. Jenks, Carol Kauffman, Robert Krause, Me Linh Luong, Shruti Malik, Vincent Marconi, Rodrigo Martino, Sanjay R. Mehta, Lisa Meintker, Andrea Mocná, Michele I. Morris, Alessandro C. Pasqualotto, Atul Patel, Olaf Penack, Nicolas Pichon, Mathias W. Pletz, Carlos Seas, Uluhan Sili, Monica Slavin, Kenji Uno, Jose A. Vazquez, Thomas Weber, Barbora Weinbergerova, Deniz Yilmaz-Karapinar, Seda Yilmaz-Semerci, Jin Yu

Infectious Disease

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Objectives: Emerging invasive fungal infections (IFI) have become a notable challenge. Apart from the more frequently described fusariosis, lomentosporiosis, mucormycosis, scedosporiosis, and certain dematiaceae or yeasts, little is known about extremely rare IFI. Methods: Extremely rare IFI collected in the FungiScope^Ⓡ registry were grouped as Dematiaceae, Hypocreales, Saccharomycetales, Eurotiales, Dermatomycetes, Agaricales, and Mucorales. Results: Between 2003 and June 2019, 186 extremely rare IFI were documented in FungiScope^Ⓡ. Dematiaceae (35.5%), Hypocreales (23.1%), Mucorales (11.8%), and Saccharomycetales (11.3%) caused most IFI. Most patients had an underlying malignancy (38.7%) with acute leukemia accounting for 50% of cancers. Dissemination was observed in 26.9% of the patients. Complete or partial clinical response rate was 68.3%, being highest in Eurotiales (82.4%) and in Agaricales (80.0%). Overall mortality rate was 29.3%, ranging from 11.8% in Eurotiales to 50.0% in Mucorales. Conclusions: Physicians are confronted with a complex variety of fungal pathogens, for which treatment recommendations are lacking and successful outcome might be incidental. Through an international consortium of physicians and scientists, these cases of extremely rare IFI can be collected to further investigate their epidemiology and eventually identify effective treatment regimens.

Original language	English (US)
Pages (from-to)	802-815
Number of pages	14
Journal	Journal of Infection
Volume	81
Issue number	5
DOIs	https://doi.org/10.1016/j.jinf.2020.08.015
State	Published - Nov 2020

Keywords

Invasive fungal infections
Mold
Rare
Registry
Yeast

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1016/j.jinf.2020.08.015

Cite this

Salmanton-García, J., Koehler, P., Kindo, A., Falces-Romero, I., García-Rodríguez, J., Ráčil, Z., Chen, S. C. A., Klimko, N., Desoubeaux, G., Thompson, G. R., Benítez-Peñuela, M. Á., Rodríguez, J. Y., Sheppard, D. C., Hoenigl, M., Le Govic, Y., Badali, H., Baddley, J. W., Chander, J., Ingram, P. R., ... Yu, J. (2020). Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope^Ⓡ—Global Registry for Emerging Fungal Infections. Journal of Infection, 81(5), 802-815. https://doi.org/10.1016/j.jinf.2020.08.015

Salmanton-García, J, Koehler, P, Kindo, A, Falces-Romero, I, García-Rodríguez, J, Ráčil, Z, Chen, SCA, Klimko, N, Desoubeaux, G, Thompson, GR, Benítez-Peñuela, MÁ, Rodríguez, JY, Sheppard, DC, Hoenigl, M, Le Govic, Y, Badali, H, Baddley, JW, Chander, J, Ingram, PR, Pakstis, DL, Mellinghoff, SC, Atıcı, S, Cesaro, S, Chakrabarti, A, Dupont, D, González, GM, Hatvani, L, Herbrecht, R, Klyasova, G, Lass-Flörl, C, Mareș, M, Mullane, K, Vinh, DC, Wisplinghoff, H, Lackner, M, Cornely, OA, Seidel, D, Alexander, BD, Almagro-Molto, M, Álvarez-Duarte, E, Avilés-Robles, M, Barać, A, Chrenková, V, Cornejo-Juárez, P, Desbois-Nogard, N, Fernández-Ruiz, M, Figueira, L, García-Martínez, J, Gräber, S, Graf, B, Haerter, G, Haider, S, Hartman, P, Heinemann, M, Ikram, A, Janvier, F, Jenks, JD, Kauffman, C, Krause, R, Luong, ML, Malik, S, Marconi, V, Martino, R, Mehta, SR, Meintker, L, Mocná, A, Morris, MI, Pasqualotto, AC, Patel, A, Penack, O, Pichon, N, Pletz, MW, Seas, C, Sili, U, Slavin, M, Uno, K, Vazquez, JA, Weber, T, Weinbergerova, B, Yilmaz-Karapinar, D, Yilmaz-Semerci, S & Yu, J 2020, 'Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope^Ⓡ—Global Registry for Emerging Fungal Infections', Journal of Infection, vol. 81, no. 5, pp. 802-815. https://doi.org/10.1016/j.jinf.2020.08.015

@article{907b2c563a7041f2965b1aedc41a2a81,

title = "Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScopeⓇ—Global Registry for Emerging Fungal Infections",

abstract = "Objectives: Emerging invasive fungal infections (IFI) have become a notable challenge. Apart from the more frequently described fusariosis, lomentosporiosis, mucormycosis, scedosporiosis, and certain dematiaceae or yeasts, little is known about extremely rare IFI. Methods: Extremely rare IFI collected in the FungiScopeⓇ registry were grouped as Dematiaceae, Hypocreales, Saccharomycetales, Eurotiales, Dermatomycetes, Agaricales, and Mucorales. Results: Between 2003 and June 2019, 186 extremely rare IFI were documented in FungiScopeⓇ. Dematiaceae (35.5%), Hypocreales (23.1%), Mucorales (11.8%), and Saccharomycetales (11.3%) caused most IFI. Most patients had an underlying malignancy (38.7%) with acute leukemia accounting for 50% of cancers. Dissemination was observed in 26.9% of the patients. Complete or partial clinical response rate was 68.3%, being highest in Eurotiales (82.4%) and in Agaricales (80.0%). Overall mortality rate was 29.3%, ranging from 11.8% in Eurotiales to 50.0% in Mucorales. Conclusions: Physicians are confronted with a complex variety of fungal pathogens, for which treatment recommendations are lacking and successful outcome might be incidental. Through an international consortium of physicians and scientists, these cases of extremely rare IFI can be collected to further investigate their epidemiology and eventually identify effective treatment regimens.",

keywords = "Invasive fungal infections, Mold, Rare, Registry, Yeast",

author = "Jon Salmanton-Garc{\'i}a and Philipp Koehler and Anupma Kindo and Iker Falces-Romero and Julio Garc{\'i}a-Rodr{\'i}guez and Zden{\v e}k R{\'a}{\v c}il and Chen, {Sharon C.A.} and Nikolai Klimko and Guillaume Desoubeaux and Thompson, {George R.} and Ben{\'i}tez-Pe{\~n}uela, {Miguel {\'A}ngel} and Rodr{\'i}guez, {Jos{\'e} Yesid} and Sheppard, {Donald C.} and Martin Hoenigl and {Le Govic}, Yohann and Hamid Badali and Baddley, {John W.} and Jagdish Chander and Ingram, {Paul R.} and Pakstis, {Diana L.} and Mellinghoff, {Sibylle C.} and Serkan Atıcı and Simone Cesaro and Arunaloke Chakrabarti and Damien Dupont and Gonz{\'a}lez, {Gloria M.} and L{\'o}r{\'a}nt Hatvani and Raoul Herbrecht and Galina Klyasova and Cornelia Lass-Fl{\"o}rl and Mihai Mareș and Kathleen Mullane and Vinh, {Donald C.} and Hilmar Wisplinghoff and Michaela Lackner and Cornely, {Oliver A.} and Danila Seidel and Alexander, {Barbara D.} and Mar{\'i}a Almagro-Molto and Eduardo {\'A}lvarez-Duarte and Martha Avil{\'e}s-Robles and Aleksandra Bara{\'c} and Vanda Chrenkov{\'a} and Patricia Cornejo-Ju{\'a}rez and Nicole Desbois-Nogard and Mario Fern{\'a}ndez-Ruiz and Luis Figueira and Jes{\'u}s Garc{\'i}a-Mart{\'i}nez and Sandra Gr{\"a}ber and Barbara Graf and Georg Haerter and Shariq Haider and Pamela Hartman and Melina Heinemann and Aamer Ikram and Fr{\'e}d{\'e}ric Janvier and Jenks, {Jeffrey D.} and Carol Kauffman and Robert Krause and Luong, {Me Linh} and Shruti Malik and Vincent Marconi and Rodrigo Martino and Mehta, {Sanjay R.} and Lisa Meintker and Andrea Mocn{\'a} and Morris, {Michele I.} and Pasqualotto, {Alessandro C.} and Atul Patel and Olaf Penack and Nicolas Pichon and Pletz, {Mathias W.} and Carlos Seas and Uluhan Sili and Monica Slavin and Kenji Uno and Vazquez, {Jose A.} and Thomas Weber and Barbora Weinbergerova and Deniz Yilmaz-Karapinar and Seda Yilmaz-Semerci and Jin Yu",

note = "Funding Information: OAC reports grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen Pharmaceuticals, Medicines Company, MedPace, Melinta Therapeutics, Merck/MSD, Pfizer, and Scynexis and personal fees from Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, F2G, Entasis, Gilead, Grupo Biotoscana, Matinas, MedPace, Menarini Ricerche, Merck/MSD, Nabriva Therapeutics Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Roche Diagnostics, Scynexis, Seres Therapeutics, and Tetraphase outside the submitted work. Funding Information: CLF reports grants from Astellas Pharma and Gilead Sciences; personal fees from Angelini, Basilea, Biomerieux, Gilead Sciences, and Merck Sharp and Dohme; and other support from Astellas Pharma, Basilea, Biomerieux, Gilead Sciences, and Merck Sharp and Dohme, outside the submitted work. Funding Information: MH reports grants from Gilead, outside the submitted work. Funding Information: RH reports grants from Gilead, Novartis, and Pfizer and personal fees from Astellas, Basilea, Gilead, MSD, Novartis, and Pfizer, outside the submitted work. Funding Information: KM reports grants as a clinical trial investigator from Gilead Sciences, Inc., clinical research grants from Ansun, Astellas, Merck, Rebiotix, Scynexis, and Shire; and consultant fees/honoraria from Chimerix, GlaxoSmithKline, Merck, and Scynexis outside the submitted work. Funding Information: DCV reports support from Avir Pharma, Cidara Therapeutics, CSL Behring, and Fonds de la Recherche en Sant{\'e} du Quebec, during the conduct of the study (salary support), outside the submitted work. Funding Information: The authors thank Susann Blo?feld for her administrative and technical assistance. FungiScope? is supported by unrestricted grants of Amplyx Pharmaceuticals, Basilea Pharmaceutica, Cidara Therapeutics, F2G Ltd. Matinas BioPharma, MSD Sharp & Dohme GmbH, and SCYNEXIS Inc. FungiScope? has been supported in the past by unrestricted grants of Astellas Pharma, Gilead Sciences, and Pfizer Inc. Publisher Copyright: {\textcopyright} 2020 The British Infection Association",

year = "2020",

month = nov,

doi = "10.1016/j.jinf.2020.08.015",

language = "English (US)",

volume = "81",

pages = "802--815",

journal = "Journal of Infection",

issn = "0163-4453",

publisher = "W.B. Saunders Ltd",

number = "5",

}

TY - JOUR

T1 - Needles in a haystack

T2 - Extremely rare invasive fungal infections reported in FungiScopeⓇ—Global Registry for Emerging Fungal Infections

AU - Salmanton-García, Jon

AU - Koehler, Philipp

AU - Kindo, Anupma

AU - Falces-Romero, Iker

AU - García-Rodríguez, Julio

AU - Ráčil, Zdeněk

AU - Chen, Sharon C.A.

AU - Klimko, Nikolai

AU - Desoubeaux, Guillaume

AU - Thompson, George R.

AU - Benítez-Peñuela, Miguel Ángel

AU - Rodríguez, José Yesid

AU - Sheppard, Donald C.

AU - Hoenigl, Martin

AU - Le Govic, Yohann

AU - Badali, Hamid

AU - Baddley, John W.

AU - Chander, Jagdish

AU - Ingram, Paul R.

AU - Pakstis, Diana L.

AU - Mellinghoff, Sibylle C.

AU - Atıcı, Serkan

AU - Cesaro, Simone

AU - Chakrabarti, Arunaloke

AU - Dupont, Damien

AU - González, Gloria M.

AU - Hatvani, Lóránt

AU - Herbrecht, Raoul

AU - Klyasova, Galina

AU - Lass-Flörl, Cornelia

AU - Mareș, Mihai

AU - Mullane, Kathleen

AU - Vinh, Donald C.

AU - Wisplinghoff, Hilmar

AU - Lackner, Michaela

AU - Cornely, Oliver A.

AU - Seidel, Danila

AU - Alexander, Barbara D.

AU - Almagro-Molto, María

AU - Álvarez-Duarte, Eduardo

AU - Avilés-Robles, Martha

AU - Barać, Aleksandra

AU - Chrenková, Vanda

AU - Cornejo-Juárez, Patricia

AU - Desbois-Nogard, Nicole

AU - Fernández-Ruiz, Mario

AU - Figueira, Luis

AU - García-Martínez, Jesús

AU - Gräber, Sandra

AU - Graf, Barbara

AU - Haerter, Georg

AU - Haider, Shariq

AU - Hartman, Pamela

AU - Heinemann, Melina

AU - Ikram, Aamer

AU - Janvier, Frédéric

AU - Jenks, Jeffrey D.

AU - Kauffman, Carol

AU - Krause, Robert

AU - Luong, Me Linh

AU - Malik, Shruti

AU - Marconi, Vincent

AU - Martino, Rodrigo

AU - Mehta, Sanjay R.

AU - Meintker, Lisa

AU - Mocná, Andrea

AU - Morris, Michele I.

AU - Pasqualotto, Alessandro C.

AU - Patel, Atul

AU - Penack, Olaf

AU - Pichon, Nicolas

AU - Pletz, Mathias W.

AU - Seas, Carlos

AU - Sili, Uluhan

AU - Slavin, Monica

AU - Uno, Kenji

AU - Vazquez, Jose A.

AU - Weber, Thomas

AU - Weinbergerova, Barbora

AU - Yilmaz-Karapinar, Deniz

AU - Yilmaz-Semerci, Seda

AU - Yu, Jin

N1 - Funding Information: OAC reports grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen Pharmaceuticals, Medicines Company, MedPace, Melinta Therapeutics, Merck/MSD, Pfizer, and Scynexis and personal fees from Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, F2G, Entasis, Gilead, Grupo Biotoscana, Matinas, MedPace, Menarini Ricerche, Merck/MSD, Nabriva Therapeutics Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Roche Diagnostics, Scynexis, Seres Therapeutics, and Tetraphase outside the submitted work. Funding Information: CLF reports grants from Astellas Pharma and Gilead Sciences; personal fees from Angelini, Basilea, Biomerieux, Gilead Sciences, and Merck Sharp and Dohme; and other support from Astellas Pharma, Basilea, Biomerieux, Gilead Sciences, and Merck Sharp and Dohme, outside the submitted work. Funding Information: MH reports grants from Gilead, outside the submitted work. Funding Information: RH reports grants from Gilead, Novartis, and Pfizer and personal fees from Astellas, Basilea, Gilead, MSD, Novartis, and Pfizer, outside the submitted work. Funding Information: KM reports grants as a clinical trial investigator from Gilead Sciences, Inc., clinical research grants from Ansun, Astellas, Merck, Rebiotix, Scynexis, and Shire; and consultant fees/honoraria from Chimerix, GlaxoSmithKline, Merck, and Scynexis outside the submitted work. Funding Information: DCV reports support from Avir Pharma, Cidara Therapeutics, CSL Behring, and Fonds de la Recherche en Santé du Quebec, during the conduct of the study (salary support), outside the submitted work. Funding Information: The authors thank Susann Blo?feld for her administrative and technical assistance. FungiScope? is supported by unrestricted grants of Amplyx Pharmaceuticals, Basilea Pharmaceutica, Cidara Therapeutics, F2G Ltd. Matinas BioPharma, MSD Sharp & Dohme GmbH, and SCYNEXIS Inc. FungiScope? has been supported in the past by unrestricted grants of Astellas Pharma, Gilead Sciences, and Pfizer Inc. Publisher Copyright: © 2020 The British Infection Association

PY - 2020/11

Y1 - 2020/11

N2 - Objectives: Emerging invasive fungal infections (IFI) have become a notable challenge. Apart from the more frequently described fusariosis, lomentosporiosis, mucormycosis, scedosporiosis, and certain dematiaceae or yeasts, little is known about extremely rare IFI. Methods: Extremely rare IFI collected in the FungiScopeⓇ registry were grouped as Dematiaceae, Hypocreales, Saccharomycetales, Eurotiales, Dermatomycetes, Agaricales, and Mucorales. Results: Between 2003 and June 2019, 186 extremely rare IFI were documented in FungiScopeⓇ. Dematiaceae (35.5%), Hypocreales (23.1%), Mucorales (11.8%), and Saccharomycetales (11.3%) caused most IFI. Most patients had an underlying malignancy (38.7%) with acute leukemia accounting for 50% of cancers. Dissemination was observed in 26.9% of the patients. Complete or partial clinical response rate was 68.3%, being highest in Eurotiales (82.4%) and in Agaricales (80.0%). Overall mortality rate was 29.3%, ranging from 11.8% in Eurotiales to 50.0% in Mucorales. Conclusions: Physicians are confronted with a complex variety of fungal pathogens, for which treatment recommendations are lacking and successful outcome might be incidental. Through an international consortium of physicians and scientists, these cases of extremely rare IFI can be collected to further investigate their epidemiology and eventually identify effective treatment regimens.

AB - Objectives: Emerging invasive fungal infections (IFI) have become a notable challenge. Apart from the more frequently described fusariosis, lomentosporiosis, mucormycosis, scedosporiosis, and certain dematiaceae or yeasts, little is known about extremely rare IFI. Methods: Extremely rare IFI collected in the FungiScopeⓇ registry were grouped as Dematiaceae, Hypocreales, Saccharomycetales, Eurotiales, Dermatomycetes, Agaricales, and Mucorales. Results: Between 2003 and June 2019, 186 extremely rare IFI were documented in FungiScopeⓇ. Dematiaceae (35.5%), Hypocreales (23.1%), Mucorales (11.8%), and Saccharomycetales (11.3%) caused most IFI. Most patients had an underlying malignancy (38.7%) with acute leukemia accounting for 50% of cancers. Dissemination was observed in 26.9% of the patients. Complete or partial clinical response rate was 68.3%, being highest in Eurotiales (82.4%) and in Agaricales (80.0%). Overall mortality rate was 29.3%, ranging from 11.8% in Eurotiales to 50.0% in Mucorales. Conclusions: Physicians are confronted with a complex variety of fungal pathogens, for which treatment recommendations are lacking and successful outcome might be incidental. Through an international consortium of physicians and scientists, these cases of extremely rare IFI can be collected to further investigate their epidemiology and eventually identify effective treatment regimens.

KW - Invasive fungal infections

KW - Mold

KW - Rare

KW - Registry

KW - Yeast

UR - http://www.scopus.com/inward/record.url?scp=85091481893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091481893&partnerID=8YFLogxK

U2 - 10.1016/j.jinf.2020.08.015

DO - 10.1016/j.jinf.2020.08.015

M3 - Article

C2 - 32798532

AN - SCOPUS:85091481893

VL - 81

SP - 802

EP - 815

JO - Journal of Infection

JF - Journal of Infection

SN - 0163-4453

IS - 5

ER -